You are here: Industry Insights > Novartis

News List

Novartis’ branaplam gets orphan drug designation for Huntington’s disease pharmaceutical-technology
October 22, 2020
The US Food and Drug Administration (FDA) has granted orphan drug designation to Novartis’ branaplam (LMI070) to treat Huntington’s disease.
NICE recommends Novartis’ Mayzent on the heels of SMC approval pharmatimes
October 16, 2020
The National Institute for Health and Care Excellence (NICE) has recommended Novartis’ Mayzent for use by NHS England, only a few days after the Scottish Medicines Consortium (SMC) approved the multiple sclerosis (MS) drug.
Merck KGaA out-licenses osteoarthritis programme to Novartis pharmatimes
October 10, 2020
Germany’s Merck KGaA has entered into an out-licensing agreement with Novartis for the development of an osteoarthritis clinical-stage programme.
BioNTech to Acquire GMP Manufacturing Site americanpharmaceuticalreview
September 27, 2020
BioNTech announced the signing of a share purchase agreement with Novartis AG, Basel / Switzerland to acquire their GMP certified manufacturing facility in Marburg, Germany.
Novartis faces delay in expansion of SMA drug Zolgensma indication pharmaceutical-technology
September 27, 2020
Novartis is facing a delay in expansion of indication for its spinal muscular atrophy (SMA) drug Zolgensma (onasemnogene abeparvovec).
Novartis Reports Positive Topline Results from Beovu for Diabetic Macular Edema americanpharmaceuticalreview
September 21, 2020
Novartis reported the first interpretable results of the Phase III KITE study, assessing the efficacy and safety of Beovu® (brolucizumab) 6 mg in diabetic macular edema (DME).
BioNTech to acquire Novartis site for Covid-19 vaccine production pharmaceutical-technology
September 21, 2020
BioNTech has signed a share purchase agreement with Novartis to acquire a manufacturing site to boost its messenger RNA (mRNA)-based BNT162 Covid-19 vaccine candidate production capacity.
BioNTech to Acquire Novartis Mfg. Site for COVID-19 Vax Production contractpharma
September 18, 2020
Will accelerate BioNTech’s efforts to scale-up commercial manufacturing capacity for its mRNA COVID-19 vaccine candidate BNT162.
Novartis’ Tafinlar plus Mekinist shows long-term benefit in advanced melanoma pharmatimes
September 18, 2020
A combination of Novartis’ cancer meds Tafinlar (dabrafenib) and Mekinist (trametinib) has demonstrated long-term benefit in advanced melanoma patients after five years of treatment.
BioNTech to buy site from Novartis to boost COVID-19 vaccine production expresspharma
September 18, 2020
The financial details of the transaction have not been revealed but the facility in Germany’s Marburg will be converted to be fully on stream in the first half of 2021 with annual production capacity up to 750 million mRNA vaccine doses.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page